Market Overview

Vetr Crowd Downgrades Celgene

Share:

The Vetr community on Monday downgraded Celgene Corporation (NASDAQ: CELG) from 4.5 stars (Strong Buy) to 4 stars (Buy). Crowd confidence was very bullish, with 100 percent of the Vetr community reporting a Buy position on the stock.

See how crowdsourced ratings could help you time the market

This upgrade came with news that Celgene would be acquiring Juno Therapeutics Inc (NASDAQ: JUNO) for $9 billion in an effort to expand its cancer treatment efforts.

Despite the downgrade, the Vetr crowd remained bullish, setting a target price of $114.80, which sits well above the current share price of $102.94. Analysts were equally as bullish, with most recent estimates sitting in the $120-$160 range.

Posted-In: VetrDowngrades Analyst Ratings

 

Related Articles (CELG + JUNO)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
PLCEB. Riley FBRDowngrades59.0
ASPUCanaccord GenuityMaintains11.0
AAPLEvercore ISI GroupMaintains305.0
FCELCraig-HallumReinstates0.500
THTXMackie ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Vetr Community Upgrades Teva Pharmaceuticals

Netflix's Big Q4 Beat Pushes Stock To New Highs, Plans To Spend Nearly $8 Billion On Content In Q1